B Cell News and Research

RSS
Treatment resistance for deadly form of kidney cancer linked to low mitochondrial content in the cell

Treatment resistance for deadly form of kidney cancer linked to low mitochondrial content in the cell

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

Researchers develop new chemistry on natural compounds to obtain a therapeutic agent for treating leukemia

Lipid-peptide nanocomplexes offer new mRNA platform

Lipid-peptide nanocomplexes offer new mRNA platform

Scientists create new fluorophores that could help fight cancer

Scientists create new fluorophores that could help fight cancer

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

COVID-19 can cause metabolism problems by interfering with insulin signaling, study reveals

COVID-19 can cause metabolism problems by interfering with insulin signaling, study reveals

Chemically modified rocaglates have a stronger effect against viral replication

Chemically modified rocaglates have a stronger effect against viral replication

A full model of the SARS-CoV-2 spike protein for studying its atomic-level dynamics by multiple microsecond simulations

A full model of the SARS-CoV-2 spike protein for studying its atomic-level dynamics by multiple microsecond simulations

Antigenic differences between early SARS-CoV-2 variants

Antigenic differences between early SARS-CoV-2 variants

Bisphosphonates appear to improve COVID-19 exposure outcomes

Bisphosphonates appear to improve COVID-19 exposure outcomes

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Machine learning can be a successful tool to predict oral cancer risk

Machine learning can be a successful tool to predict oral cancer risk

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Inhibiting pore formation in cells may facilitate prevention, treatment of NASH-associated liver cancer

Inhibiting pore formation in cells may facilitate prevention, treatment of NASH-associated liver cancer

Researchers identify orally efficacious antiviral drug against respiratory syncytial virus

Researchers identify orally efficacious antiviral drug against respiratory syncytial virus

Novel app can help doctors make better decisions for patients with leukemia.

Novel app can help doctors make better decisions for patients with leukemia.

Researchers determine optimal conditions to perform impedance cytometry

Researchers determine optimal conditions to perform impedance cytometry

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Characterization of SARS-CoV-2 Omicron persistence and infectivity among children

Characterization of SARS-CoV-2 Omicron persistence and infectivity among children

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.